Weston: ILIAD BiotechnologiesLLC, announced the selection of Emmes Group to organize upcoming events Phase III Studies of its leadership Pertussis Vaccine Candidate, BPZE1,

ILiAD selected Emmes Group for its expertise in vaccine development, agility in managing complex clinical trials, strong local market presence and integrated technology capabilities. Vaxtrials The unit has previously demonstrated efficiency and clinical trial excellence through the successful support of ILiAD’s Phase II IB-201P BPZE1 study.

Dr. Keith RubinCEO of ILIAD Biotechnologies commented, “Selecting Ames Group for our Phase III BPZE1 trials is a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ expertise in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in bringing our BPZE1 vaccine to fruition. Clinical development Plan.”

Shastri Chilukuri, Chief Executive Officer, AIMS Group, said, “We are proud and pleased that ILIAD has chosen to partner with AIMS Group to continue the clinical development of BPZE1. We look forward to working closely with ILIAD’s clinical development team on this promising new vaccine that could substantially reduce the infectivity and incidence of B. pertussis, especially in vulnerable populations.”